<DOC>
	<DOCNO>NCT00937521</DOCNO>
	<brief_summary>This study aim assess safety immunogenicity different dos formulation new Novartis Meningococcal B Recombinant Vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Dose-Ranging Formulation-Finding Meningococcal B ( MenB ) Vaccine Study 2-month-old Infants</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antipyretics</mesh_term>
	<criteria>Healthy 2month old infant ( 5589 day , inclusive ) , bear full term pregnancy , gestational age ≥ 37 week birth weight ≥ 2.5 kg Available visit schedule study parent/legal guardian willing/able comply protocol requirement Any meningococcal B C vaccine administration Prior vaccination Diphtheria , Tetanus , Pertussis ( acellular whole cell ) , Polio ( either Inactivated Oral ) , Haemophilus influenzae type b ( Hib ) , Pneumococcal antigens ; Any ascertain suspected disease cause N. meningitidis Household contact and/or intimate exposure individual laboratory confirm N. meningitidis History severe allergic reaction previous vaccination Recent significant acute chronic infection Oral parenteral antibiotic treatment 7 day prior schedule blood draw ; Any serious chronic progressive disease accord judgment investigator ( e.g. , neoplasm , diabetes mellitus Type I , cardiac disease , hepatic disease , progressive neurological disease seizure , either associate fever part underlie neurological disorder syndrome , autoimmune disease , HIV infection AIDS , blood dyscrasia diathesis , sign cardiac renal failure severe malnutrition ) Any impairment/alteration immune system result ( example ) : Receipt immunosuppressive therapy time since birth Receipt immunostimulants time since birth Use systemic corticosteroid chronic use inhale highpotency corticosteroid time since birth Receipt blood , blood product and/or plasma derivative parenteral immunoglobulin preparation Participation another clinical trial Family member household member research staff History seizure Any contraindication paracetamol</criteria>
	<gender>All</gender>
	<minimum_age>55 Days</minimum_age>
	<maximum_age>89 Days</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Antibody</keyword>
	<keyword>Infants</keyword>
</DOC>